Short Interest in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Increases By 41.3%

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) was the recipient of a large increase in short interest in August. As of August 15th, there was short interest totalling 474,600 shares, an increase of 41.3% from the July 31st total of 336,000 shares. Based on an average trading volume of 90,000 shares, the short-interest ratio is currently 5.3 days. Approximately 5.9% of the company’s stock are sold short.

NRx Pharmaceuticals Trading Down 2.7 %

NRXP traded down $0.05 during midday trading on Thursday, reaching $1.83. The company’s stock had a trading volume of 43,138 shares, compared to its average volume of 223,344. The stock has a market cap of $19.58 million, a P/E ratio of -0.59 and a beta of 1.26. The company has a fifty day simple moving average of $2.25 and a 200 day simple moving average of $14.61. NRx Pharmaceuticals has a twelve month low of $1.68 and a twelve month high of $7.33.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.06. Sell-side analysts expect that NRx Pharmaceuticals will post -4 earnings per share for the current year.

Institutional Trading of NRx Pharmaceuticals

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. AdvisorShares Investments LLC bought a new position in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 642,632 shares of the company’s stock, valued at approximately $296,000. AdvisorShares Investments LLC owned 0.75% of NRx Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 4.27% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Ascendiant Capital Markets reduced their price objective on NRx Pharmaceuticals from $50.00 to $43.00 and set a “buy” rating for the company in a research note on Friday, June 7th. HC Wainwright raised their price target on NRx Pharmaceuticals from $2.00 to $19.00 and gave the stock a “buy” rating in a research note on Monday, August 5th.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.